Literature DB >> 28455234

Optimal adaptive group sequential design with flexible timing of sample size determination.

Lu Cui1, Lanju Zhang2, Bo Yang3.   

Abstract

Flexible sample size designs, including group sequential and sample size re-estimation designs, have been used as alternatives to fixed sample size designs to achieve more robust statistical power and better trial efficiency. In this work, a new representation of sample size re-estimation design suggested by Cui et al. [5,6] is introduced as an adaptive group sequential design with flexible timing of sample size determination. This generalized adaptive group sequential design allows one time sample size determination either before the start of or in the mid-course of a clinical study. The new approach leads to possible design optimization on an expanded space of design parameters. Its equivalence to sample size re-estimation design proposed by Cui et al. provides further insight on re-estimation design and helps to address common confusions and misunderstanding. Issues in designing flexible sample size trial, including design objective, performance evaluation and implementation are touched upon with an example to illustrate.
Copyright © 2017. Published by Elsevier Inc.

Keywords:  Information fraction; Interim analysis; Power; Sample size; Type I error rate

Mesh:

Year:  2017        PMID: 28455234     DOI: 10.1016/j.cct.2017.04.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  2 in total

1.  Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).

Authors:  Rui-Fang Zhu; Yu-Lu Gao; Sue-Ho Robert; Jin-Ping Gao; Shi-Gui Yang; Chang-Tai Zhu
Journal:  J Transl Med       Date:  2020-07-06       Impact factor: 5.531

2.  Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial.

Authors:  Martin Forster; Stephen Brealey; Stephen Chick; Ada Keding; Belen Corbacho; Andres Alban; Paolo Pertile; Amar Rangan
Journal:  Clin Trials       Date:  2021-08-18       Impact factor: 2.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.